Illumina appoints Joydeep Goswami as CFO

Illumina announced Joydeep Goswami has been appointed CFO, effective immediately. Goswami previously served as Illumina’s Chief Strategy and Corporate Development Officer and interim CFO. As CFO, Goswami will be responsible for the Company’s financial planning and analysis, accounting, investor relations, internal audit, tax, and treasury functions. He will also continue to lead the corporate development and strategic planning function. Goswami assumed all CFO responsibilities on an interim basis in July 2022 and has served as Chief Strategy and Corporate Development Officer since 2019. With more than 20 years of experience in the life sciences industry, Goswami has held various senior and international management roles with P&L responsibility. Prior to joining Illumina, he was President, Clinical Next Generation Sequencing (NGS) and Oncology at Thermo Fisher Scientific, where he led the expanded application of NGS across clinical oncology, research, and reproductive health segments. While at Thermo Fisher, he also served as President, Asia Pacific and Japan leading the integration of Life Technologies APJ business into the regional Thermo Fisher organization, doubling organic growth while significantly improving the profitability of the business. Earlier in his career, Goswami was President, Japan at Life Technologies where he drove strong top and bottom-line growth through key customer engagement. Goswami began his career at McKinsey & Company, where he managed projects and teams serving global clients spanning several industries including pharmaceuticals, medical products, chemical, private equity and technology.